# Pharmacokinetics and Safety in Healthy Volunteers

> **NCT02045979** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 327 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 695501
- **DRUG:** adalimumab-EU source
- **DRUG:** adalimumab-US source

## Key facts

- **NCT ID:** NCT02045979
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-31
- **Primary completion:** 2014-06-20
- **Final completion:** 2014-06-20
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045979, "Pharmacokinetics and Safety in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02045979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*